Please use this identifier to cite or link to this item:
|Title:||Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features||Authors:||Forsyth, Cecily J ;Godfrey, A.L.;Campbell, P.J.;MacLean, C.;Buck, G.;Cook, J.;Temple, J.;Wilkins, B.S.;Wheatley, K.;Nangalia, J.;Grinfeld, J.;McMullin, M.F.;Kiladjian, J.J.;Green, A.R.;Harrison, C.N.||Affliation:||Central Coast Local Health District
|Issue Date:||Aug-2018||Source:||36(34):3361-3369||Journal title:||Journal of Clinical Oncology||Department:||Haematology||Abstract:||Purpose Cytoreductive therapy is beneficial in patients with essential thrombocythemia (ET) at high risk of thrombosis. However, its value in those lacking high-risk features remains unknown. This open-label, randomized trial compared hydroxycarbamide plus aspirin with aspirin alone in patients with ET age 40 to 59 years and without high-risk factors or extreme thrombocytosis. Patients and Methods Patients were age 40 to 59 years and lacked a history of ischemia, thrombosis, embolism, hemorrhage, extreme thrombocytosis (platelet count ≥ 1,500 × 109/L), hypertension, or diabetes requiring therapy. In all, 382 patients were randomly assigned 1:1 to hydroxycarbamide plus aspirin or aspirin alone. The composite primary end point was time to arterial or venous thrombosis, serious hemorrhage, or death from vascular causes. Secondary end points were time to first arterial or venous thrombosis, first serious hemorrhage, death, incidence of transformation, and patient-reported quality of life. Results After a median follow-up of 73 months and a total follow-up of 2,373 patient-years, there was no significant difference between the arms in the likelihood of patients reaching the primary end point (hazard ratio, 0.98; 95% CI, 0.42 to 2.25; P = 1.0). The incidence of significant vascular events was low, at 0.93 per 100 patient-years (95% CI, 0.61 to 1.41). There were also no differences in overall survival; in the composite end point of transformation to myelofibrosis, acute myeloid leukemia, or myelodysplasia; in adverse events; or in patient-reported quality of life. Conclusion In patients with ET age 40 to 59 years and lacking high-risk factors for thrombosis or extreme thrombocytosis, preemptive addition of hydroxycarbamide to aspirin did not reduce vascular events, myelofibrotic transformation, or leukemic transformation. Patients age 40 to 59 years without other clinical indications for treatment (such as previous thrombosis or hemorrhage) who have a platelet count < 1,500 × 109/L should not receive cytoreductive therapy.||URI:||https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1285||DOI:||10.1200/jco.2018.78.8414||Pubmed:||https://www.ncbi.nlm.nih.gov/pubmed/30153096||ISSN:||0732-183x||Publicaton type:||Journal Article||Keywords:||Haematology
|Study or Trial:||Randomized Controlled Clinical Trial/Controlled Clinical Trial|
|Appears in Collections:||Haematology|
Show full item record
checked on Jan 28, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.